Immuno-Oncology

non-CME

HUB

The Role of Neoadjuvant Immune Checkpoint Blockade for Infiltrating Breast Cancer and DCIS

HUB Moderator(s)

• 

  Farin Amersi, MD (she/her/hers)

  Associate Professor of Surgery
  Cedars-Sinai Medical Center
  Los Angeles , California, United States

  Disclosure information not submitted.

The role of neoadjuvant therapy for patients with both invasive cancer and pre-malignant breast disease is rapidly evolving. The purpose of this session is to review current data and ongoing trials to provide guidance on breast cancer treatment, including specific immunotherapies and surgical timing.

Presentations:

• 4:03pm – 4:15pm ET

  The Role of Neoadjuvant Immune Checkpoint Blockade for Infiltrating Breast Cancer
  

  HUB Presenter: Elizabeth A. Mittendorf, MD, PhD, MHCM (she/her/hers) – Brigham and Women's Hospital, Dana Farber Cancer Institute
• 4:15pm – 4:27pm ET

  The Role of Neoadjuvant Immune Checkpoint Blockade for DCIS
  

  HUB Presenter: E. Shelley Hwang, MD, MPH – Duke University School of Medicine
• 4:27pm – 4:30pm ET

  Questions & Discussion